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ABSTRACT 34 
 35 
BACKGROUND: 36 
Premature infants often require oxygen supplementation and, therefore, are exposed to oxidative stress. 37 
Following oxygen exposure, preterm infants frequently develop chronic lung disease and have a 38 
significantly increased risk of asthma. 39 
OBJECTIVE: 40 
We sought to identify the underlying mechanisms by which neonatal hyperoxia promotes asthma 41 
development. 42 
METHODS: 43 
Mice were exposed to neonatal hyperoxia followed by a period room air recovery. A group of mice were 44 
also intranasally exposed to house dust mite antigen (HDM). Assessments were performed at various time 45 
points for evaluation of airway hyperresponsiveness (AHR), eosinophilia, mucus production, 46 
inflammatory gene expression, T helper (Th) and group 2 innate lymphoid cell (ILC2) responses. Sera 47 
from term- and preterm-born infants were also collected and the levels of IL-33 and type 2 cytokines were 48 
measured. 49 
RESULTS: 50 
Neonatal hyperoxia induced asthma-like features including AHR, mucus hyperplasia, airway eosinophilia, 51 
and type 2 pulmonary inflammation. In addition, neonatal hyperoxia promoted allergic Th responses to 52 
HDM exposure. Elevated IL-33 levels and ILC2 responses were observed in the lungs most likely due to 53 
oxidative stress caused by neonatal hyperoxia. IL-33 receptor signaling and ILC2s were vital for the 54 
induction of asthma-like features following neonatal hyperoxia. Serum IL-33 levels correlated 55 
significantly with serum levels of IL-5 and IL-13, but not IL-4 in preterm infants. 56 
CONCLUSION: 57 
These data demonstrate that an axis involving IL-33 and ILC2s is important for the development of 58 
asthma-like features following neonatal hyperoxia and suggest therapeutic potential for targeting IL-33, 59 
ILC2s, and oxidative stress to prevent and/or treat asthma development related to prematurity. 60 
 61 
KEY WORDS 62 
Neonatal hyperoxia, Oxidative stress, Asthma, IL-33, ILC2s 63 
 64 
 65 
 66 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3 
CAPSULE SUMMARY 67 
Elevated IL-33 production and enhanced group 2 innate lymphoid cell (ILC2) responses promote the 68 
development of asthma-like features related to prematurity and neonatal oxygen exposure 69 
 70 
 71 
KEY MESSAGES 72 
Neonatal hyperoxia induces the development of asthma-like features in mice 73 
Enhanced IL-33 production and ILC2 responses promote the development of asthma-like features 74 
following neonatal hyperoxia 75 
Serum IL-33 levels correlate with IL-5 and IL-13 levels in preterm infants 76 
 77 
 78 
 79 
 80 
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 98 
 99 
 100 
 101 
INTRODUCTION 102 
Preterm birth (born before 37 weeks of gestation) affects about 10% pregnancies 1. Chronic pulmonary 103 
complications of preterm birth are common, and include bronchopulmonary dysplasia (BPD) and asthma 104 
2, 3
. Compared to children born full term, children born significantly preterm had about three times the risk 105 
of developing chronic wheezing and asthma disorders later in their lives 4. The molecular and 106 
immunological mechanisms underlying the wheezing and asthma associated with prematurity are 107 
currently unclear.  108 
 109 
At birth, infants born significantly preterm are likely to require life-supporting respiratory support with 110 
positive pressure ventilation and supplemental oxygen. Because the preterm lung is normally developed 111 
in a relatively hypoxic intrauterine environment, even exposure to room air (RA, 21% oxygen 112 
concentration) is considered hyperoxic and constitutes an oxidative stress 5. Exposure to higher degrees 113 
and durations of hyperoxia results in significant neonatal lung injury, interrupted lung development, and 114 
ultimately the development of BPD 6-8. The lungs of term newborn mice are developmentally and 115 
structurally comparable with lungs of human infants born around 26 to 28 weeks' gestation9.  Therefore 116 
hyperoxia exposure of newborn mice offers a useful model for investigating the roles of premature 117 
oxygen exposure in regulating lung development and chronic diseases in infants born very prematurely. 118 
Using a murine neonatal hyperoxia model, it has been shown that neonatal hyperoxia inhibited the 119 
development of alveolar-capillary membrane structure and impaired lung gas-exchange function, similar 120 
to findings observed in human BPD 10, 11. Neonatal hyperoxia also alters lung inflammation status and 121 
immune cell compositions 12, which may contribute to the enhanced inflammatory response against 122 
influenza virus infection in adult age 13, 14.  In addition, neonatal hyperoxia promotes airway 123 
hyperresponsiveness (AHR) to methacholine challenge 15, 16, but the underlying molecular and cellular 124 
mechanisms were not investigated. 125 
Innate lymphoid cells (ILCs) have recently been identified as innate counterparts of T helper (Th) cells 126 
that are capable of secreting large amounts of cytokines upon stimulation 17. Based on their cytokine 127 
secretion, ILCs can be divided into three groups; group 1 innate lymphoid cells (ILC1s) produce Th1 128 
cytokine IFN-γ, group 2 innate lymphoid cells (ILC2s) produce large amount of IL-5 and IL-13, and 129 
group 3 innate lymphoid cells (ILC3s) secret Th17 cytokines IL-17 and IL-22 17, 18. In the lungs, ILC2s 130 
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appear to be the major ILC subset and respond to epithelial cell-derived cytokines including IL-25, IL-33 131 
and thymic stromal lymphopoietin (TSLP) 19-21. Enhanced ILC2 activities have been observed in a variety 132 
of murine asthma models and human clinical asthma studies 22, 23. Interestingly, recent evidence shows 133 
that ILC2s are accumulated following spontaneous IL-33 release at the alveolar phase of lung 134 
development and contribute to the Th2-mediated allergic asthma development later in life 24, 25. To this 135 
end, ILC2s promote antigen uptake and dendritic cell migration to the lung-draining lymph nodes, thereby 136 
facilitating the induction of Th2 responses against allergens 24, 26. Thus ILC2s appear to be one of the key 137 
drivers for innate and adaptive immunity in asthma development, particularly at the neonatal stages. 138 
However, it remains largely unclear whether neonatal ILC2 development and function are regulated by 139 
various external environmental factors (e.g. hyperoxia), thereby influencing the development of pediatric 140 
asthma. 141 
We found that neonatal hyperoxia promoted asthma-like immunologic and physiologic features in mice 142 
and further enhanced allergic Th2 and Th17 responses in the respiratory tract following allergen exposure. 143 
Neonatal hyperoxia promoted IL-33 expression in the developing lungs and enhanced ILC2 expansion 144 
was required for the development of asthma-like features.  The Nrf2 agonist, sulforaphane (SFN), reduced 145 
lung IL-33 levels and ILC2 responses, supporting the role of oxidative stress in the promotion of ILC2s in 146 
the lung. Furthermore, genetic ablation of the IL-33 receptor, ST2, decreased asthma-related gene 147 
expression, eosinophil recruitment, and ILC2 responses following neonatal hyperoxia. Finally, in preterm 148 
infants, we found that serum IL-33 levels positively correlated with serum IL-5 and IL-13, but not IL-4 149 
levels. Our findings suggest that, in infants experiencing oxidative stress as a result of premature birth, IL-150 
33 and ILC2s may play an important role in promoting the development of asthma-related features. 151 
 152 
 153 
 154 
 155 
 156 
 157 
 158 
 159 
 160 
 161 
 162 
MATERIAL AND METHODS 163 
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 164 
Ethics statement 165 
All animal experiments were approved by the Institutional Animal Care and U se Committee of Indiana 166 
University School of Medicine and the Mayo Clinic. 167 
Blood samples were obtained from infants who were born full term or premature following IRB approval 168 
and written parental consent.  169 
 170 
Mouse and neonatal hyperoxia model 171 
C57BL/6, Rag1-/- and Rag2/Il2rg-/- mice were purchased from the Jackson Laboratories (Bar Harbor, 172 
ME). Il1rl1-/- (ST2-deficient) mice were provided by Dr. McKenzie from MRC Laboratory of Molecular 173 
Biology. All mice are in C57BL/6 genetic background. Female mice were primarily used in the study as 174 
our own data and previous data have suggested male mice failed to exhibit significantly enhanced AHR 175 
following neonatal hyperoxia 15. The controls of ST2 KO were age-matched C57/BL6 mice. For 176 
Rag2/Il2rg-/- mice, age-matched C57/BL6 and Rag1-/- mice were the controls. For neonatal hyperoxia 177 
model, within 24 hours of birth, two or more litters of wild-type C57BL/6 mice were pooled and 178 
separated into two equal groups and housed with a single dam in a standard cage. One cage was placed 179 
within a 30″ × 20″ × 20″ polypropylene chamber (BioSpherix, Lacona, NY) in which the oxygen 180 
concentration was maintained at >80% O2, and the other was maintained in room air (RA; 21% O2). 181 
Nursing dams were rotated every 24 hours between RA and O2 groups to avoid oxygen toxicity in dams. 182 
Following hyperoxia exposure from postnatal (PN) day PN0-PN7, the mice were returned to room air 183 
until sacrifice or HDM challenge. HDM extract (Greer Laboratories, NC) were administrated intranasally 184 
(10 µg/20 µl) to mouse 10 times (three times per week) for 4 weeks. After 2 days from the last 185 
administration of HDM, mice were sacrificed for cellular analysis. To stimulate Nrf2 activity, mice were 186 
intraperitoneal injected with sulforaphane (SFN) at 25 mg/kg daily from PN7 until PN 21.  187 
 188 
Measurement of AHR 189 
AHR to methacholine challenged was measured using the FinePoint RC system (Buxco Research 190 
Systems, Wilmington, NC) and the airflow was recorded in individual mice according to the 191 
manufacturer’s guidelines. Briefly, mice were anesthetized and a tracheostomy tube was inserted and 192 
connected to a ventilator. After 5 min of stabilization followed by administration of PBS, airway 193 
resistance was determined by dose responsiveness to aerosolized methacholine (Sigma-Aldrich, St. Louis, 194 
MO) delivered by a nebulizer. 195 
 196 
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Lung single cell preparation  197 
For airway cells, Broncho-alveolar lavage (BAL) was obtained by flushing the airway multiple times with 198 
400 µl aliquots of sterile PBS, followed by centrifugation to collect airway cells. For lung single cell 199 
suspensions, lungs were perfused with PBS, chopped to small pieces using scissors, and digested with 200 
5ml of 183 U/ml collagenase type 2 (Worthington Biochemical Corporation, Lakewood, NJ). After 40 201 
min, lung pieces were dispersed by passage through a 70 µM strainer and RBC lysed with ACK buffer. 202 
For cytokine detection in lung, lungs were mechanically separated by passage through a strainer, which 203 
was subsequently rinsed with 400 µl of PBS. After centrifugation, supernatants were collected to 204 
determine cytokine protein levels by ELISA. 205 
 206 
Quantitative RT-PCR 207 
RNA from lung homogenates was isolated using an RNA isolation kit (Sigma-Aldrich) according to the 208 
manufacturer’s instructions and reverse transcribed into cDNA using random primers (Invitrogen, Grand 209 
Island, NY) and MMLV (Invitrogen). cDNAs were amplified using SYBR Green PCR Master Mix 210 
(Applied Biosystems, Grand Island, NY) using 7500 Fast-PCR or quantistudio 3 PCR system (Applied 211 
Biosystems). Data were generated by the comparative threshold cycle (∆CT) method by normalizing to 212 
hypoxanthine-guanine phosphoribosyltransferase (HPRT). 213 
 214 
Epithelial cell culture 215 
Mouse epithelial cells (MLE-12) were and cultured in DMEM/F-12 medium supplemented with 2 % FBS 216 
(Hyclone), 1% insulin-Transferrin-Selenium (Gibco), 10 nM hydrocortisone, 10 nM beta-estradiol, L-217 
glutamine 2 mM (Sigma-Aldrich), 10 mM HEPES. To induce oxidative stress, MLE-12 cells were treated 218 
with indicated concentrations of H2O2 in the presence or absence of 10 µM SFN for 24 hr. Then RNA was 219 
extracted for the measurement of Il33 gene expression. For hyperoxia culture of epithelial cells, MLE-12 220 
cells were cultured in > 70% O2 concentrations for 24 hours in the presence or absence of SFN (10 µM). 221 
Cells were then cultured in normoxia for an additional 24 hours. Il33 gene expression was determined by 222 
quantitative RT-PCR. 223 
 224 
PCR array 225 
cDNA were obtained from pooled (6-8 lungs) samples per group and mixed with SYBR Green PCR 226 
Master Mix. The mixture was used for analysis with mouse asthma and allergy RT2 PCR array or mouse 227 
oxidative stress RT2 PCR array (Qiagen, Frederick, MD) according to the manufacturer’s instructions. 228 
Data was analyzed by RT2 PCR profiler array data analyses software in SABiosciences website. 229 
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 230 
Determination of ROS levels 231 
To measure intracellular ROS levels in epithelial cells, lung single cell suspensions were surface stained 232 
with antibodies conjugated with fluorescence (ant-CD45 and anti-EpCAM) first. Cells were then stained 233 
with 10 µM CM-H2DCFDA (Molecular Probes, Carlsbad, CA) at 37°C for 30 min. Cells were washed 234 
and analyzed immediately by flow cytometry. Cells that were treated with 50 µM of H2O2 served as the 235 
positive control. 236 
 237 
Flow Cytometry 238 
To quantify ILC2s, lung single cells were stained with fluorescent conjugated lineage markers (Lin: 239 
CD11b, CD11c, CD3, B220, Ter-119, Gr-1, NK1.1, TCRβ), anti-Thy1.2, anti-CD25, anti-CD127 and 240 
anti-ST2. ILC2s were identified as Lin- Th1.2+ CD25+ and CD127+. For neutrophil and eosinophil 241 
identification, lung or BAL cells were stained with fluorescent conjugated anti-CD45, anti-CD11b, anti-242 
CD11c, anti-Siglec F, anti-Ly6G, and anti-Ly6C. Eosinophils were identified as CD45+ CD11b+ Siglec F+ 243 
and CD11c-, while neutrophils were identified as CD45+ CD11b+ Ly6G+.  Total DCs (CD45+, SiglecF-, 244 
Ly6G-, CD11chi, MHC IIhi), FcεRI+ DCs (CD45+, SiglecF-, Ly6G-, FcεRIα+, CD11chi, HMC IIhi), mast 245 
cells (CD45+, SiglecF-, Ly6G-, CD11c-, CD11b-/int, FcεRI+, c-Kit+) and basophils (CD45+, SiglecF-, Ly6G-246 
, CD11c-, CD11b-/int, FcεRI+, c-Kit-, CD49b+) were quantified based on the there surface markers 247 
indicated above. For intracellular staining, cells were restimulated with 100 ng/ml of PMA (Sigma-248 
Aldrich), 1µg/ml of ionomycin (Sigma-Aldrich) and 40U/ml of hIL-2 in the presence of 1µg/ml of 249 
Golgistop (BD Biosciences, San Diego, CA) for 5 hours. Then cells were stained with surface Abs and 250 
fixed/permeabilized with BD Cytofix/Cytoperm kit for staining with cytokine Abs. All fluorescent 251 
conjugated antibodies were purchased from Biolegend (San Diego, CA), BD Biosciences or eBioscience 252 
(San Diego, CA). Samples were acquired through BD LSR II Flow Cytometer (BD Biocience) or Attune 253 
NXT flow cytometer (Life technologies). Data were analyzed by using FlowJo software (Treestar, 254 
Ashland, OR). 255 
 256 
ELISA 257 
Cytokines in the supernatants of lung homogenates were measured with IL-33 ELISA kit (eBioscience) or 258 
TSLP ELISA kit (Biolegend) according to the manufacturer’s instructions. 259 
 260 
Histology 261 
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At PN 28, whole lungs were harvested and fixed in 10% formaldehyde (Fisher Scientific, Fair Lawn, NJ) 262 
for 48hr and stored in PBS until embedding. Fixed lung tissues were embedded in paraffin, sectioned at 5-263 
µm thickness and stained with hematoxylin and eosin or Periodic Acid Schiff (PAS) by the Indiana 264 
University Pathology Laboratory. Histological scores (ranges 1-4) were performed on PAS stained slides 265 
blindly by two independent observers. To quantify the percentage of areas stained with PAS within 266 
airway epithelium of lung specimens, computer-based image analysis was performed based on a previous 267 
report 62. Briefly, each image was set with scale bar as size per pixel using Image-Pro Premier 3D (Media 268 
Cybernetics, Rockville, MD). The areas of airway epithelium and the areas of PAS positive airway 269 
epithelium were computer traced based on the differential colored pixels. PAS-positive areas in the 270 
epithelium and areas of total airway epithelium were recorded in randomly selected airway sections (~5) 271 
per lung tissue section. The percentage of PAS positive area was calculated based on the ratio of PAS 272 
positive areas to the total areas of airway epithelium in each lung section.   273 
 274 
Clinical samples 275 
Sera were collected from children with at 3 - 30 months of corrected age who were born prematurely (<37 276 
gestation week) or maturely and determined cytokine levels using multiplex (Millipore, Billerica, MA) 277 
according to the manufacturer’s instructions. All data points are from individual patients. 278 
 279 
Statistical Analysis 280 
Data were expressed in mean values ± SEM. One-way ANOVA, two-way ANOVA with subsequent 281 
Fisher’s LSD test or t test were used to determine the significance of differences between groups using 282 
GraphPad Prism software. For clinical data, correlations were evaluated by Pearson’s test using GraphPad 283 
Prism (Graphpad, La Jolla, CA). 284 
 285 
 286 
RESULTS 287 
Neonatal hyperoxia promotes AHR, mucus production and type 2 airway inflammation 288 
We have utilized a murine neonatal hyperoxia model to replicate the high concentration of oxygen 289 
(relative to the hypoxic levels experienced in utero) delivered to lungs of infants born preterm 5, 27. To 290 
mimic the lung injury experienced by preterm infants, for the first 7 postnatal days (PN7) we exposed 291 
neonatal mice to either hyperoxia (80% oxygen, O2) or room air (21% oxygen, RA) (Fig. 1A). To 292 
understand the long-term effects of neonatal hyperoxia exposure, all mice were then housed in RA for an 293 
additional 21 days and their AHR assessed. Consistent with previous reports 15, 16, we found that 294 
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compared to mice raised entirely in RA, mice previously exposed to neonatal hyperoxia showed 295 
significantly higher AHR (Fig. 1B). In line with our previous report 28, histological analysis showed that 296 
lungs from O2-exposed mice had simplified alveolar structure (Fig. 1C). Strikingly, neonatal hyperoxia 297 
exposure was associated with mucus hyperplasia (Fig. 1C, D, E). In addition, lungs of O2-exposed mice 298 
displayed a significant increase in expression of mucus-associated genes (Clca1 and Muc5ac) (Fig. 1F). 299 
The expression of type 2 cytokines IL-5 and IL-13, but not IFN-γ, IL-17 and IL-4, were also significantly 300 
increased in the lungs from O2-exposed mice, suggesting that these mice have enhanced type 2 airway 301 
inflammation (Fig. 1G). Further, mice exposed to neonatal hyperoxia also showed airway eosinophilia 302 
(Fig. 1H). Interestingly, prior exposure to neonatal hyperoxia was also associated with airway neutrophilia 303 
(Fig. 1I).  Together, these results demonstrate that neonatal hyperoxia promotes the development of 304 
multiple cardinal features of asthma-like symptoms including AHR, mucus production, type 2 305 
inflammation, and recruitment of eosinophils and neutrophils.  306 
 307 
Neonatal hyperoxia leads to enhanced lung ILC2 responses at the pediatric stage 308 
We sought to identify the cellular mechanisms underlying the development of AHR and type 2 309 
inflammation associated with prior exposure to neonatal hyperoxia. To quantify IL-13 producing cells, we 310 
performed intracellular cytokine staining for single cell suspensions obtained from lungs of RA or O2-311 
exposed mice. Consistent with our gene expression data (Fig. 1F), compared to those of RA-exposed 312 
mice, lungs of O2 -exposed mice contained a significantly higher proportion of IL-13 producing cells (Fig. 313 
2A, B and C). The majority of the IL-13 producing cells lacked CD4 expression (CD4-) (Fig. 2A, B), 314 
indicating they were not Th2 cells. ILC2s are recently-identified, lineage-negative innate immune cells 315 
capable of producing large amounts of type 2 cytokines 22. We found that the majority of lung IL-13 316 
producing cells were lineage-negative (Lin-) (Fig. 2A, C), suggesting that they are ILC2s. Indeed, these 317 
Lin- IL-13-producing cells also expressed CD25 and CD127 (Fig. S1), further supporting their identity as 318 
ILC2s. Extensive surface-marker analysis confirmed the expression of ST2, ICOS, CD90, KLRG1 and 319 
low levels of IL-17RB, the typical markers of ILC2s (Fig. 2D). In the lungs from RA or O2-exposed mice 320 
at PN7, the relative frequency and absolute number of ILC2s were not different (Fig. 2E). However, lungs 321 
from O2-exposed mice showed increased ILC2 frequency and/or numbers than those of RA-exposed mice 322 
at PN14 and PN28 (Fig. 2E). The levels of lung ILC2 responses were comparable between RA and O2-323 
exposed mice at PN58 (Fig. 2E). O2-exposed mice also exhibited enhanced total dendritic cells (DCs), 324 
FcεRI+ DCs and basophils in the lungs at PN28 (Fig. S2).  325 
 326 
AHR and pulmonary type 2 inflammation are mediated by ILC2s  327 
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To determine the roles of ILC2s in the development of AHR and type 2 inflammation, we exposed Rag1-/- 328 
mice (deficient in T and B cells) and Rag2-/-/Il2rg-/- mice (deficient in T, B and ILCs) to RA or neonatal 329 
hyperoxia (as in Fig. 1A) and measured AHR at PN28. Similar to WT mice, O2-exposed Rag1-/- mice 330 
showed increased airway responsiveness, suggesting that T and B cells are dispensable for AHR 331 
development following neonatal hyperoxia (Fig. 3A). In contrast, O2-exposed Rag2-/- /Il2rg-/- mice showed 332 
AHR comparable to RA-exposed Rag1-/- or Rag2-/-/Il2rg-/- mice, indicating that for AHR development 333 
following neonatal hyperoxia ILCs are critical. Compared to those of O2-exposed Rag1-/- mice,  334 
histological analysis in the O2-exposed Rag2-/-/Il2rg-/- mice were comparable to RA-controls and 335 
demonstrated diminished airway mucus production (Fig. 3 B, C, D, E). Furthermore, although O2-exposed 336 
Rag1-/-  mice exhibited increased eosinophilia compared to those of RA-exposed Rag1-/-  mice, O2-337 
exposed Rag2-/-/Il2rg-/- mice showed airway eosinophilia similar to those of RA-exposed control mice 338 
(Rag1-/- or  Rag2-/-/Il2rg-/-) (Fig. 3F). These data suggest that while Th2 cells are dispensable, ILC2s are 339 
essential for the development of neonatal hyperoxia-induced AHR, mucous production, and type 2 340 
inflammation. 341 
 342 
Neonatal hyperoxia promotes allergic inflammation  343 
Besides AHR, children and adolescents formerly born preterm exhibit enhanced development of allergic 344 
asthma 29.  In addition, pre-clinical murine models have established that ILC2s are capable of enhancing 345 
adaptive Th2 responses following intranasal papain challenge 26. We therefore hypothesized that mice 346 
formerly exposed to neonatal hyperoxia would demonstrate elevated allergic responses to subsequent 347 
airway allergen exposure. To test this, we administered HDM intranasally (i.n.) to RA- or O2-exposed WT 348 
mice for 4 weeks starting at PN28 and examined Th responses at PN56 (Fig. 4A). We chose PN28 for 349 
HDM challenge because maximal differences in ILC2 responses between RA- and O2-exposed mice were 350 
observed at this timepoint (Fig. 2E).  As shown previously 30, 31, chronic HDM exposure in both groups 351 
increased airway inflammation, eosinophilia and neutrophilia (Fig. 4B). However, HDM-challenged O2-352 
exposed mice exhibited a significantly exaggerated response as evidenced by higher numbers of airway 353 
eosinophils and neutrophils compared to those of HDM-challenged RA-exposed mice. We also observed 354 
increased numbers of IL-4, IL-13 and IL-17 producing Lin+ cells present in the airway (Fig. 4C, D) and 355 
increased IL-13-producing cells in the lungs (Fig. S3) of HDM-challenged O2-exposed mice compared to 356 
those of HDM-challenged RA-exposed mice. At PN 56, both at baseline (Fig. 2E) and following HDM 357 
exposure, the frequencies and absolute numbers of ILC2s between RA- and O2-exposed groups were not 358 
different (Fig. S4). Notably, the majority of the IL-17 producing cells following HDM challenge were 359 
Lin+ (Fig. S3), indicating that T cells rather than ILC3s were likely the main IL-17 producing cells 360 
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following HDM challenge in both RA and O2-exposed mice. Together, these data indicate that exposure 361 
of neonates to hyperoxia, later exacerbates development of allergic inflammation following respiratory 362 
allergen challenge.  363 
 364 
Activation of the anti-oxidant pathway attenuates IL-33 and ILC2 responses 365 
To explore the molecular mechanisms that drive enhanced ILC2 responses and type 2 inflammation 366 
resulting from neonatal hyperoxia exposure, we examined the expression of epithelial-derived cytokines 367 
including IL-25, IL-33 and TSLP, which have been shown to be important for inciting ILC2 responses 20. 368 
In the lungs of O2-exposed mice at the conclusion of neonatal hyperoxia exposure (PN7) and following 7d 369 
of recovery in room air (PN14), mRNA expression of Tslp and Il33 were increased, respectively (Fig. 370 
5A). While TSLP protein levels were undetectable in both RA and O2-exposed lungs, in the lungs of O2-371 
exposed mice we verified increased levels of IL-33 protein at PN21 (Fig. 5B). We did not observe 372 
measurable IL-33 in bronchoalveolar lavage (BAL) fluid (data not shown), possibly due to the immediate 373 
depletion of the low levels of IL-33 produced following O2-exposure. Hyperoxia can increase oxidative 374 
stress via the accumulation of reactive oxygen species (ROS)32. We found that oxidative stress genes were 375 
upregulated and epithelial cell ROS production was increased in lungs previously exposed to neonatal 376 
hyperoxia (Fig. S5 A, B), suggesting that O2-exposed lungs exhibited increased oxidative stress. To test 377 
the hypothesis that oxidative stress facilitates Il33 expression, we exposed mouse airway epithelial cells to 378 
H2O2 in vitro and then determined Il33 (Fig. 5C). Treatment with H2O2 increased Il33 expression in 379 
epithelial cells (Fig. 5C). Nrf2 is a major transcription factor regulating cellular anti-oxidant responses 33, 380 
34
 and its agonist SFN has been used to attenuate oxidative stress and associated inflammation 35, 36. SFN 381 
treatment diminished both basal Il33 expression and Il33 upregulation following H2O2 exposure, 382 
indicating that Nrf2 activation could attenuate Il33 expression in epithelial cells (Fig. 5D). Consistent 383 
with this notion, epithelial cells cultured under hyperoxia conditions exhibited enhanced Il33 expression 384 
in vitro, which was dampened by SFN treatment (Fig. 5E). Importantly, treatment of mice with SFN in 385 
vivo during neonatal hyperoxia attenuated the upregulation of a number of oxidative stress genes (Fig. 386 
S5B) and impaired the observed increase in IL-33 protein levels following neonatal hyperoxia (Fig. 5F). 387 
IL-33 has been shown to be a major driver of neonatal ILC2 expansion 24. We therefore examined ILC2 388 
responses following SFN treatment. Although SFN treatment tended to increase baseline ILC2 levels in 389 
RA-exposed mice, treatment of SFN in O2-exposed mice blunted the observed increase in both ILC2s and 390 
Lin-/IL-13 producing cells at PN 28 following hyperoxia (Fig. 5 G, H). Taken together, these data 391 
indicated that oxidative stress resulting from neonatal hyperoxia enhances IL-33 expression during 392 
recovery, which may contribute to expansion and activation of ILC2s.  393 
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 394 
ILC2 responses following neonatal hyperoxia are mediated by IL-33 signaling 395 
To determine whether IL-33 signaling is required for type 2 lung inflammation and ILC2 responses 396 
following neonatal hyperoxia, we exposed WT and IL-33 receptor-deficient (ST2-/-) mice to RA or 397 
neonatal hyperoxia (as in Fig. 1A) and assessed lung gene expression and ILC2 responses at PN28 (Fig. 398 
6). Using allergy and asthma PCR-gene array, compared to those of RA-exposed WT mice whole lung 399 
RNA from O2-exposed WT mice showed increased expression of many asthma-related genes. Strikingly, 400 
the majority of upregulated genes observed in O2-exposed WT mice were not upregulated similarly and 401 
remained similar to RA-exposed levels in lungs of O2-exposed ST2-deficient mice (Fig. 6A and Fig. S6), 402 
suggesting that IL-33 signaling is an important contributor of the altered allergy and asthma gene 403 
expression profiles following neonatal hyperoxia. A number of differentially expressed genes including 404 
Arg1, Il21, Il5, Il13, Pmch and Rnase2a were confirmed with RT-PCR (Fig. 6B). Furthermore, compared 405 
to those of O2-exposed WT mice, O2-exposed ST2-deficient mice showed diminished frequency and 406 
numbers of ILC2s in the lungs, suggesting that following neonatal hyperoxia, IL-33 signaling is critical 407 
for the expansion of ILC2s (Fig. 6C). Following neonatal hyperoxia, in the absence of IL-33 signaling 408 
both IL-13 and IL-5 producing ILC2s were significantly decreased (Fig. 6D). Consistent with diminished 409 
ILC2s in the lungs, in response to neonatal hyperoxia ST2-deficient mice failed to develop airway 410 
eosinophilia (Fig. 6E). Together, these results suggest that IL-33 signaling via ST2 is critically important 411 
for the expression of asthma-related genes, ILC2 responses and airway inflammation following neonatal 412 
hyperoxia. 413 
 414 
Serum IL-33 levels correlate with IL-5 and IL-13 levels in preterm infants 415 
To determine if the relationship between IL-33 and type 2 cytokines established in the mouse model is 416 
conserved in preterm infants, we analyzed the levels of IL-33 and type 2 cytokine concentrations in sera 417 
obtained from children (aged 3- 30 months) that had been born either term or preterm (Table S1). Likely 418 
due to the limited sample size and varied sample collection timepoint, the levels of IL-33 and type 2 419 
cytokines such as IL-5, IL-13 and IL-4 in the sera of preterm infants were not significantly different with 420 
those of term infants (Fig. S7A), although we observed a trend toward increased percentages of 421 
individuals having high serum IL-33 levels in preterm infants, particularly in those infants who met 422 
criteria for BPD (Fig. S7B). We also observed a trend toward increased percentages of individuals having 423 
high serum IL-33 levels in the group of infants born before 30 weeks’ gestation (Fig. S7C). Interestingly, 424 
there was a significant correlation between serum concentrations of IL-33 and IL-5, and serum 425 
concentrations of IL-33 and IL-13 within the preterm group (Fig. 7A, B) but not in term infant group (Fig. 426 
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S8). In addition, we found that there were significant correlations between serum IL-33 and IL-13, serum 427 
IL-33 and IL-5 levels in sera collected in infants younger than 18 months of age, but not those of sera 428 
collected from infants between 18 and 30 months of age (Fig. S9).  429 
 430 
Although IL-4 production by ILC2s has been described, unlike IL-13, it is not required for induction of 431 
TH2 responses 26, 37. We found that serum IL-33 levels did not significantly correlate with serum IL-4 432 
levels in preterm infants (Fig. 7, C). The sum of these clinical data corroborate our findings in the pre-433 
clinical neonatal hyperoxia model: following hyperoxia, we observed increased IL-5 and IL-13 in 434 
association with increased IL-33, which is required for ILC2 expansion. Thus, although future studies on 435 
respiratory IL-33 and type 2 cytokine levels in preterm infants with larger sample sizes are warranted, 436 
these data suggest the proof of principle that an IL-33-ILC2 axis could be a reasonable contributor of 437 
asthma-like airway inflammation in preterm infants.   438 
 439 
 440 
 441 
 442 
 443 
 444 
DISCUSSION 445 
Infants born extremely premature often require supplemental oxygen therapy for their survival. However, 446 
in preterm infants and in pre-clinical animal models, oxygen supplementation has been associated with 447 
interrupted distal lung development, chronic deficits in gas exchange, airway hyper-reactivity, and 448 
chronic pulmonary dysfunction 38-40. Numerous studies have established various detrimental effects of 449 
neonatal hyperoxia on lung structural and functional development 27, 41 42. However, the mechanisms by 450 
which neonatal hyperoxia mediates pulmonary inflammation, abnormal lung development, and chronic 451 
pulmonary dysfunction are largely unknown. We show here that neonatal hyperoxia enhanced lung IL-33 452 
production and ILC2 responses, thereby resulting in AHR, mucous production and type 2 inflammation. 453 
Strikingly, we found that neonatal hyperoxia also exaggerated pulmonary allergic responses to respiratory 454 
allergen challenge. Our findings suggest that an axis involving IL-33 and ILC2s is vital for the 455 
development of asthma-related pathology following neonatal hyperoxia.   456 
 457 
Our observation that young-adult mice previously subjected to neonatal hyperoxia for the first PN7 (the 458 
period of saccular and rapid alveolar development) show AHR is in agreement with previous studies of a 459 
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similar developmental window 15, 43. We further demonstrated here that neonatal hyperoxia promoted the 460 
development of other asthma-like features including mucus production, airway eosinophilia and 461 
neutrophilia and increased expression of type 2 cytokines IL-5 and IL-13. Thus neonatal hyperoxia leads 462 
to the development of multiple asthma-like features at the pediatric and young-adult stages. These results 463 
are consistent with the data that asthma-like symptoms and AHR are frequently reported in children, 464 
adolescents, and young adults that were born very premature and developed BPD 44-46. Notably, neonatal 465 
T cells are prone to developing into Th2-type cells following infection or antigenic challenge via T cell-466 
intrinsic and extrinsic mechanisms47-49. It is thus of interest that ILC2s, rather than Th2 cells, are 467 
increased in the lungs and required for development of asthma-like symptoms following neonatal 468 
hyperoxia. While atopic asthma driven by Th2 cells are responsive to specific antigens or allergens, 469 
ILC2s that are driven by hyperoxia are unlikely responsive to specific antigens but driven by cytokines 470 
released by reactive epithelial cells. This difference may underlie the fact that some features of asthma 471 
and AHR subsequent to extremely premature birth differed from typical allergic childhood asthma 50.  472 
 473 
In addition to AHR and type 2 inflammation, we found that neonatal hyperoxia also increased host 474 
sensitivity to allergen challenge as reflected by elevated type 2 and type 17 inflammation observed in the 475 
lungs following HDM challenge. Notably, previous findings have found that neonatal hyperoxia did not 476 
enhance allergic responses to ovalbumin (OVA) challenge 15. This could be due to the differences in 477 
allergens or sensitization routes used as OVA was given through i.p. previously 15, whereas HDM was 478 
delivered i.n. in our study. ILC2s have been shown to facilitate sensitization to local, but not systemic, 479 
Th2-inducing allergen exposures 51. Thus, it is possible that enhanced ILC2 responses following neonatal 480 
hyperoxia specifically enhance respiratory, but not systemic, allergen sensitization.  Consistent with this 481 
concept, IL-13-derived from ILC2s was shown to enhance allergic responses through the promotion of 482 
dendritic cell migration to lung-draining mediastinal lymph nodes for the priming of naïve CD4 T cells. 483 
ILC2s have also been shown to mediate memory Th2 cell activation 52 and can acquire memory-like 484 
properties to enhance allergic lung inflammation months after their initial activation 53. Thus, ILC2s could 485 
be a central regulator in the induction of both innate and adaptive immunity during the development of 486 
AHR and allergic asthma in response to allergens in infants born prematurely. Future studies are 487 
warranted to establish the specific roles and underlying mechanisms by which ILC2s may play to promote 488 
Th2 and Th17 responses following neonatal hyperoxia.  489 
 490 
Airway epithelial-derived IL-25, TSLP and IL-33 have been shown to enhance ILC2 expansion and/or 491 
cytokine production 21, 54-58. We found that IL-25 expression was comparable between RA and O2-492 
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exposed mice, suggesting that for the induction of enhanced ILC2 responses following neonatal 493 
hyperoxia, IL-25 is unlikely to be vital. Conversely, both TSLP and IL-33 transcription in the lung was 494 
enhanced following neonatal hyperoxia. While the effects of TSLP on ILC2 responses are not tested in 495 
our study, data observed here have suggested a critical role of IL-33 in promoting ILC2 responses and 496 
type 2 inflammation following neonatal hyperoxia, as ST2 deficiency impaired ILC2 expansion and 497 
cytokine production. Strikingly, ST2 deficiency diminished the expression of a large numbers of asthma-498 
related genes, indicating that the IL-33-ST2 signaling axis is critical for the development of asthma-like 499 
inflammation in the lung following neonatal hyperoxia. Of note, the effects of ST2 signaling in other cell 500 
types, including eosinophils, have been documented 59. Future studies, therefore, are needed to investigate 501 
the exact roles of IL-33 signaling in ILC2s in promoting asthma-related gene expression in the lungs.  502 
Two recent studies have shown that IL-33 is released spontaneously during lung alveolarization, which 503 
drives enhanced ILC2 accumulation and asthma development at the pediatric stage 24, 25. Our results are 504 
consistent with those findings as we also observed that ILC2 percentages in the lungs reached a peak at 505 
PN14 in mice housed under room air. However, hyperoxia exposure further enhanced and sustained IL-33 506 
expression, which further promoted and sustained lung ILC2 responses till PN28. Since IL-33 production 507 
by epithelial cells is associated with lung remodeling during distal lung development, it is possible that 508 
aberrant lung alveolarization and a sustained lung remodeling process may contribute to the prolonged IL-509 
33 expression following neonatal hyperoxia 24. 510 
 511 
Our present data lead us to postulate that cellular oxidative stress may be an important factor in the 512 
production of IL-33. Increased ROS levels have been shown to contribute significantly to lung injury 60, 513 
and Nrf2 agonists given in the course of neonatal hyperoxia have been shown to dampen lung injury and 514 
promote normal distal lung development 61. Consistent with this idea, the Nrf2 agonist, SFN, dampened 515 
IL-33 expression in vitro and in vivo and decreased ILC2s in the lungs of O2-exposed mice. Interestingly, 516 
stimulation of the Nrf2 pathway appeared to elevate ILC2 responses in RA-control mice at baseline. Thus 517 
it is plausible that the beneficial effects of SFN on ILC2 responses following neonatal hyperoxia could be 518 
partially masked.  To this end, a recent paper has suggested that oxidative stress is a key checkpoint for 519 
IL-33 release by airway epithelium62. Interestingly, due to interruption of placental-fetal transfer and 520 
inadequate endogenous production, anti-oxidant responses are compromised in preterm infants 63, 64. 521 
Further, following OVA challenge in the adult age, Nrf2 agonists have been shown to inhibit Th2 522 
responses and asthma development 65. Thus, targeting oxidative stress with proper anti-oxidants could be 523 
a promising method to prevent airflow obstruction and asthma development commonly observed 524 
following preterm birth. 525 
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 526 
As a proof of principle, we measured serum IL-33 and type 2 cytokine levels in older infants formerly 527 
born preterm and compared them to age-matched term-born infants. While compared to term infants there 528 
is a trend that IL-33 concentrations are elevated in the sera of infants born prematurely, the differences did 529 
not reach statistical significance most likely due to the small sample size. However, we observed that 530 
there is a significant correlation between serum IL-33 and serum IL-5 and IL-13 levels in preterm infants. 531 
Unlike IL-13, ILC2-derived IL-4 is not required to induce TH2 responses 26. Thus, these data provide a 532 
proof of principle that IL-33-driven ILC2s responses may be relevant in the development of asthma-like 533 
symptoms observed in those of preterm infants. Indeed, IL-33 has been increasingly appreciated as a 534 
major driver of human asthma 66, 67. Notably, IL-33 activity is regulated by multiple posttranslational 535 
events including protease cleavage and oxidization 68. The IL-33 levels measured here did not 536 
differentiate the active versus non-active forms. Furthermore, we measured circulating rather than 537 
respiratory IL-33 due to the lack of accessibility to respiratory samples. In order to firmly establish the 538 
roles of IL-33 in asthma development in preterm infants, active forms of respiratory IL-33 levels should 539 
be analyzed in the future.  540 
 541 
Extremely preterm infants in the post-surfactant era are exposed to lower degrees of hyperoxia than 542 
previously.  Therefore, given the significant change in clinical practice and disease phenotype, animal 543 
models utilizing excessive hyperoxia should be assessed for their clinical-relevance.  We chose to use 544 
80% oxygen because, as we have previously published, similar levels of hyperoxia produce a durable 545 
phenotype that structurally and functionally mimics many of the aspects of post-surfactant BPD 11, 28. 546 
Recent clinical reports of extremely premature infants have consistently suggested a dose-response effect 547 
with oxygen support and lung function.  For example, in infants and children previously diagnosed with 548 
BPD, the duration of oxygen supplementation and deficits in FEV1 and DLco were positively correlated 6, 549 
69, 70
. Likewise, the severity of BPD and the degree of persistent lung dysfunction are also positively 550 
correlated 71-73. Indeed, even in premature infants that did not develop BPD, early, cumulative oxygen 551 
exposure is predictive of persistent pulmonary dysfunction 7. Although present-day neonatal care strives 552 
to reduce oxygen exposure to the lowest effective dose, many infants with significant early and persistent 553 
lung disease are routinely exposed to 40-50% oxygen on average, and many are exposed to 60-70% or 554 
higher 74-77.  Thus, while careful oxygen titration has emerged as a centerpiece of neonatal care, many 555 
infants continue to require excessive oxygen supplementation, the degree of which generally correlates 556 
with persistent lung dysfunction. As with any animal model, direct comparison to the human condition is 557 
often complex.  Given that the murine lung is designed to develop in an environment that is relatively 558 
hyperoxic compared to the human lung at the same stage, it is likely that higher levels of hyperoxia are 559 
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required to injure the murine lung to a similar degree.  While we have not systematically investigated the 560 
above-mentioned possibilities, we justify our use of the current model based on its ability to phenocopy 561 
some of the hallmark structural and functional characteristics of present-day BPD 11, 28. 562 
 563 
In conclusion, our studies have revealed that neonatal hyperoxia promotes the development of asthma-like 564 
features and enhances host reactivity to respiratory allergen. We thus have provided viable cellular and 565 
molecular mechanisms explaining enhanced asthma development in children born prematurely. Our 566 
results suggest targeting the IL-33 and ILC2 axis may be a reasonable future approach to prevent asthma 567 
development and/or treat asthma-like symptoms in children born prematurely. 568 
 569 
 570 
ACKNOWLEDGMENTS  571 
This study was supported by RO1 AI112844, AG047156 and HL126647 to J.S.; R01 AI095282, 572 
AI129241 and HL62150 to M.H.K.; RO1 HL62150 and Huvis Foundation grant to A. H. L; RO1 573 
HL117823 and RO1 AI128729 to H. K.; R01 CA168814 to S. P.; Indiana Pediatric Scientist Award and 574 
K12 HD068371 to S. K.A; RO1 HL056470 to Y.S.P.  We thank Dr. Andrew McKenzie for ST2-deficient 575 
mice. We thank nurses and physicians at IU Riley Hospital for collecting infant sera. 576 
 577 
REFERENCES: 578 
 579 
1. Rubens CE, Sadovsky Y, Muglia L, Gravett MG, Lackritz E, Gravett C. Prevention of preterm 580 
birth: harnessing science to address the global epidemic. Science translational medicine 2014; 581 
6:262sr5. 582 
2. Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia. Birth defects research. Part 583 
A, Clinical and molecular teratology 2014; 100:145-57. 584 
3. Halterman JS, Lynch KA, Conn KM, Hernandez TE, Perry TT, Stevens TP. Environmental 585 
exposures and respiratory morbidity among very low birth weight infants at 1 year of life. 586 
Archives of disease in childhood 2009; 94:28-32. 587 
4. Been JV, Lugtenberg MJ, Smets E, van Schayck CP, Kramer BW, Mommers M, et al. Preterm 588 
birth and childhood wheezing disorders: a systematic review and meta-analysis. PLoS medicine 589 
2014; 11:e1001596. 590 
5. Vogel ER, Britt RD, Jr., Trinidad MC, Faksh A, Martin RJ, MacFarlane PM, et al. Perinatal 591 
oxygen in the developing lung. Canadian journal of physiology and pharmacology 2015; 93:119-592 
27. 593 
6. Cazzato S, Ridolfi L, Bernardi F, Faldella G, Bertelli L. Lung function outcome at school age in 594 
very low birth weight children. Pediatric pulmonology 2013; 48:830-7. 595 
7. Stevens TP, Dylag A, Panthagani I, Pryhuber G, Halterman J. Effect of cumulative oxygen 596 
exposure on respiratory symptoms during infancy among VLBW infants without 597 
bronchopulmonary dysplasia. Pediatric pulmonology 2010; 45:371-9. 598 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 19
8. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of 599 
bronchopulmonary dysplasia by postnatal age in extremely premature infants. American journal of 600 
respiratory and critical care medicine 2011; 183:1715-22. 601 
9. Rieger-Fackeldey E, Park MS, Schanbacher BL, Joshi MS, Chicoine LG, Nelin LD, et al. Lung 602 
development alterations in newborn mice after recovery from exposure to sublethal hyperoxia. 603 
The American journal of pathology 2014; 184:1010-6. 604 
10. Dauger S, Ferkdadji L, Saumon G, Vardon G, Peuchmaur M, Gaultier C, et al. Neonatal exposure 605 
to 65% oxygen durably impairs lung architecture and breathing pattern in adult mice. Chest 2003; 606 
123:530-8. 607 
11. Ahlfeld SK, Gao Y, Conway SJ, Tepper RS. Relationship of structural to functional impairment 608 
during alveolar-capillary membrane development. The American journal of pathology 2015; 609 
185:913-9. 610 
12. Liao J, Kapadia VS, Brown LS, Cheong N, Longoria C, Mija D, et al. The NLRP3 inflammasome 611 
is critically involved in the development of bronchopulmonary dysplasia. Nature communications 612 
2015; 6:8977. 613 
13. O'Reilly MA, Marr SH, Yee M, McGrath-Morrow SA, Lawrence BP. Neonatal hyperoxia 614 
enhances the inflammatory response in adult mice infected with influenza A virus. American 615 
journal of respiratory and critical care medicine 2008; 177:1103-10. 616 
14. Yee M, Chess PR, McGrath-Morrow SA, Wang Z, Gelein R, Zhou R, et al. Neonatal oxygen 617 
adversely affects lung function in adult mice without altering surfactant composition or activity. 618 
American journal of physiology. Lung cellular and molecular physiology 2009; 297:L641-9. 619 
15. Regal JF, Lawrence BP, Johnson AC, Lojovich SJ, O'Reilly MA. Neonatal oxygen exposure alters 620 
airway hyper-responsiveness but not the response to allergen challenge in adult mice. Pediatric 621 
allergy and immunology : official publication of the European Society of Pediatric Allergy and 622 
Immunology 2014; 25:180-6. 623 
16. Kumar VH, Lakshminrusimha S, Kishkurno S, Paturi BS, Gugino SF, Nielsen L, et al. Neonatal 624 
hyperoxia increases airway reactivity and inflammation in adult mice. Pediatric pulmonology 625 
2016; 51:1131-41. 626 
17. Gasteiger G, Rudensky AY. Interactions between innate and adaptive lymphocytes. Nature 627 
reviews. Immunology 2014; 14:631-9. 628 
18. Artis D, Spits H. The biology of innate lymphoid cells. Nature 2015; 517:293-301. 629 
19. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new 630 
innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70. 631 
20. Martinez-Gonzalez I, Steer CA, Takei F. Lung ILC2s link innate and adaptive responses in 632 
allergic inflammation. Trends in immunology 2015; 36:189-95. 633 
21. Stier MT, Bloodworth MH, Toki S, Newcomb DC, Goleniewska K, Boyd KL, et al. Respiratory 634 
syncytial virus infection activates IL-13-producing group 2 innate lymphoid cells through thymic 635 
stromal lymphopoietin. The Journal of allergy and clinical immunology 2016; 138:814-24 e11. 636 
22. Klein Wolterink RG, Kleinjan A, van Nimwegen M, Bergen I, de Bruijn M, Levani Y, et al. 637 
Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of 638 
allergic asthma. European journal of immunology 2012; 42:1106-16. 639 
23. Smith SG, Chen R, Kjarsgaard M, Huang C, Oliveria JP, O'Byrne PM, et al. Increased numbers of 640 
activated group 2 innate lymphoid cells in the airways of patients with severe asthma and 641 
persistent airway eosinophilia. The Journal of allergy and clinical immunology 2016; 137:75-86 642 
e8. 643 
24. de Kleer IM, Kool M, de Bruijn MJ, Willart M, van Moorleghem J, Schuijs MJ, et al. Perinatal 644 
Activation of the Interleukin-33 Pathway Promotes Type 2 Immunity in the Developing Lung. 645 
Immunity 2016; 45:1285-98. 646 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 20
25. Steer CA, Martinez-Gonzalez I, Ghaedi M, Allinger P, Matha L, Takei F. Group 2 innate 647 
lymphoid cell activation in the neonatal lung drives type 2 immunity and allergen sensitization. 648 
The Journal of allergy and clinical immunology 2017. 649 
26. Halim TY, Steer CA, Matha L, Gold MJ, Martinez-Gonzalez I, McNagny KM, et al. Group 2 650 
innate lymphoid cells are critical for the initiation of adaptive T helper 2 cell-mediated allergic 651 
lung inflammation. Immunity 2014; 40:425-35. 652 
27. Domm W, Misra RS, O'Reilly MA. Affect of Early Life Oxygen Exposure on Proper Lung 653 
Development and Response to Respiratory Viral Infections. Frontiers in medicine 2015; 2:55. 654 
28. Cox AM, Gao Y, Perl AT, Tepper RS, Ahlfeld SK. Cumulative effects of neonatal hyperoxia on 655 
murine alveolar structure and function. Pediatric pulmonology 2017; 52:616-24. 656 
29. Goncalves C, Wandalsen G, Lanza F, Goulart AL, Sole D, Dos Santos A. Repercussions of 657 
preterm birth on symptoms of asthma, allergic diseases and pulmonary function, 6-14 years later. 658 
Allergologia et immunopathologia 2016; 44:489-96. 659 
30. Tashiro H, Takahashi K, Hayashi S, Kato G, Kurata K, Kimura S, et al. Interleukin-33 from 660 
Monocytes Recruited to the Lung Contributes to House Dust Mite-Induced Airway Inflammation 661 
in a Mouse Model. PloS one 2016; 11:e0157571. 662 
31. Lei Y, Boinapally V, Zoltowska A, Adner M, Hellman L, Nilsson G. Vaccination against IL-33 663 
Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma. 664 
PloS one 2015; 10:e0133774. 665 
32. Bouch S, O'Reilly M, Harding R, Sozo F. Neonatal exposure to mild hyperoxia causes persistent 666 
increases in oxidative stress and immune cells in the lungs of mice without altering lung structure. 667 
American journal of physiology. Lung cellular and molecular physiology 2015; 309:L488-96. 668 
33. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its 669 
activation by oxidative stress. The Journal of biological chemistry 2009; 284:13291-5. 670 
34. Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sanchez-Perez P, Cadenas S, et al. 671 
Antioxidant responses and cellular adjustments to oxidative stress. Redox biology 2015; 6:183-97. 672 
35. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A, Yodoi J. Sulforaphane induces 673 
thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in 674 
mice. Investigative ophthalmology & visual science 2005; 46:979-87. 675 
36. McGrath-Morrow SA, Lauer T, Collaco JM, Lopez A, Malhotra D, Alekseyev YO, et al. 676 
Transcriptional responses of neonatal mouse lung to hyperoxia by Nrf2 status. Cytokine 2014; 677 
65:4-9. 678 
37. Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid 679 
cells promotes food allergy by blocking regulatory T-cell function. The Journal of allergy and 680 
clinical immunology 2016; 138:801-11 e9. 681 
38. Giannandrea M, Yee M, O'Reilly MA, Lawrence BP. Memory CD8+ T cells are sufficient to 682 
alleviate impaired host resistance to influenza A virus infection caused by neonatal oxygen 683 
supplementation. Clinical and vaccine immunology : CVI 2012; 19:1432-41. 684 
39. Fawke J, Lum S, Kirkby J, Hennessy E, Marlow N, Rowell V, et al. Lung function and respiratory 685 
symptoms at 11 years in children born extremely preterm: the EPICure study. American journal of 686 
respiratory and critical care medicine 2010; 182:237-45. 687 
40. Jaakkola JJ, Ahmed P, Ieromnimon A, Goepfert P, Laiou E, Quansah R, et al. Preterm delivery 688 
and asthma: a systematic review and meta-analysis. The Journal of allergy and clinical 689 
immunology 2006; 118:823-30. 690 
41. O'Reilly M, Sozo F, Harding R. Impact of preterm birth and bronchopulmonary dysplasia on the 691 
developing lung: long-term consequences for respiratory health. Clinical and experimental 692 
pharmacology & physiology 2013; 40:765-73. 693 
42. Ahlfeld SK, Conway SJ. Assessment of inhibited alveolar-capillary membrane structural 694 
development and function in bronchopulmonary dysplasia. Birth defects research. Part A, Clinical 695 
and molecular teratology 2014; 100:168-79. 696 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 21
43. Wang H, Jafri A, Martin RJ, Nnanabu J, Farver C, Prakash YS, et al. Severity of neonatal 697 
hyperoxia determines structural and functional changes in developing mouse airway. American 698 
journal of physiology. Lung cellular and molecular physiology 2014; 307:L295-301. 699 
44. Vollsaeter M, Roksund OD, Eide GE, Markestad T, Halvorsen T. Lung function after preterm 700 
birth: development from mid-childhood to adulthood. Thorax 2013; 68:767-76. 701 
45. Gibson AM, Doyle LW. Respiratory outcomes for the tiniest or most immature infants. Seminars 702 
in fetal & neonatal medicine 2014; 19:105-11. 703 
46. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the Short- and Long-704 
Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia. American journal 705 
of respiratory and critical care medicine 2015; 192:134-56. 706 
47. Lewis DB, Gern JE, Hill HR, Friedlander SL, La Pine TR, Lemanske RF, Jr., et al. Newborn 707 
immunology: relevance to the clinician. Current problems in pediatric and adolescent health care 708 
2006; 36:189-204. 709 
48. Hong JY, Bentley JK, Chung Y, Lei J, Steenrod JM, Chen Q, et al. Neonatal rhinovirus induces 710 
mucous metaplasia and airways hyperresponsiveness through IL-25 and type 2 innate lymphoid 711 
cells. The Journal of allergy and clinical immunology 2014; 134:429-39. 712 
49. Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, et al. Respiratory Syncytial Virus 713 
Disease Is Mediated by Age-Variable IL-33. PLoS pathogens 2015; 11:e1005217. 714 
50. Halvorsen T, Skadberg BT, Eide GE, Roksund O, Aksnes L, Oymar K. Characteristics of asthma 715 
and airway hyper-responsiveness after premature birth. Pediatric allergy and immunology : official 716 
publication of the European Society of Pediatric Allergy and Immunology 2005; 16:487-94. 717 
51. Gold MJ, Antignano F, Halim TY, Hirota JA, Blanchet MR, Zaph C, et al. Group 2 innate 718 
lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures. 719 
The Journal of allergy and clinical immunology 2014; 133:1142-8. 720 
52. Halim TY, Hwang YY, Scanlon ST, Zaghouani H, Garbi N, Fallon PG, et al. Group 2 innate 721 
lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nature 722 
immunology 2016; 17:57-64. 723 
53. Martinez-Gonzalez I, Matha L, Steer CA, Ghaedi M, Poon GF, Takei F. Allergen-Experienced 724 
Group 2 Innate Lymphoid Cells Acquire Memory-like Properties and Enhance Allergic Lung 725 
Inflammation. Immunity 2016; 45:198-208. 726 
54. Divekar R, Kita H. Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic 727 
stromal lymphopoietin) and allergic inflammation. Current opinion in allergy and clinical 728 
immunology 2015; 15:98-103. 729 
55. Kumar RK, Foster PS, Rosenberg HF. Respiratory viral infection, epithelial cytokines, and innate 730 
lymphoid cells in asthma exacerbations. Journal of leukocyte biology 2014; 96:391-6. 731 
56. Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more potent than IL-732 
25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. 733 
The Journal of allergy and clinical immunology 2013; 132:933-41. 734 
57. Monticelli LA, Buck MD, Flamar AL, Saenz SA, Tait Wojno ED, Yudanin NA, et al. Arginase 1 735 
is an innate lymphoid-cell-intrinsic metabolic checkpoint controlling type 2 inflammation. Nature 736 
immunology 2016; 17:656-65. 737 
58. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate production of 738 
T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 739 
463:540-4. 740 
59. Johnston LK, Hsu CL, Krier-Burris RA, Chhiba KD, Chien KB, McKenzie A, et al. IL-33 741 
Precedes IL-5 in Regulating Eosinophil Commitment and Is Required for Eosinophil Homeostasis. 742 
Journal of immunology 2016; 197:3445-53. 743 
60. Datta A, Kim GA, Taylor JM, Gugino SF, Farrow KN, Schumacker PT, et al. Mouse lung 744 
development and NOX1 induction during hyperoxia are developmentally regulated and 745 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 22
mitochondrial ROS dependent. American journal of physiology. Lung cellular and molecular 746 
physiology 2015; 309:L369-77. 747 
61. Ni J, Lin YG, Wu L, Huang W, Wei JF, Jiang XQ. [Protective Effect of Activated Nrf2 against 748 
Hyperoxia-induced Lung Injury in Neonatal Rats]. Sichuan da xue xue bao. Yi xue ban = Journal 749 
of Sichuan University. Medical science edition 2015; 46:399-402. 750 
62. Uchida M, Anderson EL, Squillace DL, Patil N, Maniak PJ, Iijima K, et al. Oxidative stress serves 751 
as a key checkpoint for IL-33 release by airway epithelium. Allergy 2017. 752 
63. Poggi C, Dani C. Antioxidant strategies and respiratory disease of the preterm newborn: an 753 
update. Oxidative medicine and cellular longevity 2014; 2014:721043. 754 
64. Asikainen TM, White CW. Antioxidant defenses in the preterm lung: role for hypoxia-inducible 755 
factors in BPD? Toxicology and applied pharmacology 2005; 203:177-88. 756 
65. Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, et al. Disruption of Nrf2 757 
enhances susceptibility to severe airway inflammation and asthma in mice. The Journal of 758 
experimental medicine 2005; 202:47-59. 759 
66. Gluck J, Rymarczyk B, Kasprzak M, Rogala B. Increased Levels of Interleukin-33 and Thymic 760 
Stromal Lymphopoietin in Exhaled Breath Condensate in Chronic Bronchial Asthma. 761 
International archives of allergy and immunology 2016; 169:51-6. 762 
67. Guo Z, Wu J, Zhao J, Liu F, Chen Y, Bi L, et al. IL-33 promotes airway remodeling and is a 763 
marker of asthma disease severity. The Journal of asthma : official journal of the Association for 764 
the Care of Asthma 2014; 51:863-9. 765 
68. Cohen ES, Scott IC, Majithiya JB, Rapley L, Kemp BP, England E, et al. Oxidation of the alarmin 766 
IL-33 regulates ST2-dependent inflammation. Nature communications 2015; 6:8327. 767 
69. Jacob SV, Coates AL, Lands LC, MacNeish CF, Riley SP, Hornby L, et al. Long-term pulmonary 768 
sequelae of severe bronchopulmonary dysplasia. J Pediatr 1998; 133:193-200. 769 
70. Doyle LW, Carse E, Adams AM, Ranganathan S, Opie G, Cheong JLY, et al. Ventilation in 770 
Extremely Preterm Infants and Respiratory Function at 8 Years. N Engl J Med 2017; 377:329-37. 771 
71. Keller RL, Feng R, DeMauro SB, Ferkol T, Hardie W, Rogers EE, et al. Bronchopulmonary 772 
Dysplasia and Perinatal Characteristics Predict 1-Year Respiratory Outcomes in Newborns Born at 773 
Extremely Low Gestational Age: A Prospective Cohort Study. J Pediatr 2017; 187:89-97 e3. 774 
72. Ronkainen E, Dunder T, Peltoniemi O, Kaukola T, Marttila R, Hallman M. New BPD predicts 775 
lung function at school age: Follow-up study and meta-analysis. Pediatr Pulmonol 2015; 50:1090-776 
8. 777 
73. Mourani PM, Sontag MK, Younoszai A, Miller JI, Kinsella JP, Baker CD, et al. Early pulmonary 778 
vascular disease in preterm infants at risk for bronchopulmonary dysplasia. Am J Respir Crit Care 779 
Med 2015; 191:87-95. 780 
74. Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of 781 
bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit 782 
Care Med 2011; 183:1715-22. 783 
75. Nyp M, Sandritter T, Poppinga N, Simon C, Truog WE. Sildenafil citrate, bronchopulmonary 784 
dysplasia and disordered pulmonary gas exchange: any benefits? J Perinatol 2012; 32:64-9. 785 
76. Bhat R, Salas AA, Foster C, Carlo WA, Ambalavanan N. Prospective analysis of pulmonary 786 
hypertension in extremely low birth weight infants. Pediatrics 2012; 129:e682-9. 787 
77. Laughon M, Allred EN, Bose C, O'Shea TM, Van Marter LJ, Ehrenkranz RA, et al. Patterns of 788 
respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics 789 
2009; 123:1124-31. 790 
 791 
 792 
 793 
 794 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 24
FIGURE LEGENDS 796 
 797 
Figure 1. Neonatal hyperoxia promotes AHR, mucus production and type 2 airway inflammation. 798 
(A) Experimental schemes. Neonatal mice were exposed to hyperoxia or RA for 7 days and then housed 799 
in RA until PN28 for analysis of AHR, histology and lung inflammation.  800 
(B) Airway resistance (RL) was determined following methacholine challenge in mice exposed to RA or 801 
O2. n=5 or 6 mice per group (mean ± SEM). 802 
(C) Lung sections were stained with hematoxylin and eosin (H&E) or periodic acid-Schiff (PAS).  803 
(D) Pathology scores on PAS staining sections were quantified. n=13 or 14 mice per group (mean ± 804 
SEM). 805 
(E) % of PAS-positive areas within airway epithelium was calculated by image analysis. n=13 or 14 mice 806 
per group (mean ± SEM).  807 
(F) Lung mucus associated genes were measured by quantitative RT-PCR. n=3 or 4 mice per group (mean 808 
± SEM). 809 
(G) Lung cytokine gene expressions were determined by quantitative RT-PCR. n=6 mice per group (mean 810 
± SEM). 811 
(H) The frequencies and absolute numbers of eosinophils (CD45+SiglecF+CD11c-) in BAL were 812 
measured by flow cytometry. n=3 mice per group (mean ± SEM). 813 
(I) The frequencies and absolute numbers of neutrophils (CD45+Ly6G+CD11b+) in BAL were measured 814 
by flow cytometry. n=3 mice per group (mean ± SEM). 815 
Data are representative of at least three independent experiments. n.s., not significant; * P ≤ 0.05. 816 
 817 
Figure 2. Neonatal hyperoxia promotes ILC2 responses. 818 
Mice were exposed to RA or O2 as in Fig. 1A   819 
(A) Representative FACS plot of IL-13-producing cells in the lungs. 820 
(B and C) The frequencies of IL-13+ cells in CD4- (B) or Lin- (C) were determined by flow cytometry. 821 
n=3 mice per group (mean ± SEM). 822 
(D) Expression of surface markers on ILC2s (Lin-CD25+CD127+) in mice exposed to RA or O2. 823 
(E) The frequencies and absolute numbers of ILC2s in the lungs were measured at the indicated PN days. 824 
n=3 to 7 mice per group (mean ± SEM) (mean ± SEM). 825 
Data are representative of at least two independent experiments. n.s., not significant; * P ≤ 0.05. 826 
 827 
Figure 3. AHR development and pulmonary type 2 inflammation following neonatal hyperoxia are 828 
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mediated by ILC2s. 829 
(A)  Neonatal mice were exposed to RA or O2 as in Fig. 1A and airway resistance (RL) was 830 
determined at PN 28. n=4 to 11 mice per group (mean ± SEM). 831 
(B and C) Lung sections were stained with H&E (B) or PAS (C). 832 
(D) Pathology scores on PAS staining sections were quantified. n=9 or 10 mice per group (mean ± SEM). 833 
(E) % of PAS-positive areas within airway epithelium was calculated by image analysis.  n=9 or 10 mice 834 
per group (mean ± SEM).  835 
(F) The frequencies and absolute numbers of airway eosinophils were measured by flow cytometry. n=4 836 
mice per group (mean ± SEM). 837 
Data are representative of at least two independent experiments. n.s., not significant; * P ≤ 0.05. 838 
 839 
Figure 4. Neonatal hyperoxia enhances Th2 response to subsequent HDM exposure. 840 
(A) Experimental scheme. Mice exposed to RA or O2 were exposed to HDM for 4 weeks from PN28 to 841 
PN56.  842 
(B) BAL cell counts, BAL eosinophil and neutrophil numbers were determined by flow cytometry. n=3 to 843 
5 mice per group (mean ± SEM). 844 
(C) Airway cytokine producing cells were measured by intracellular staining. n=3 or 4 mice per group 845 
(mean ± SEM). 846 
(D) Representative FACS plot of cytokine-producing cells in the airway.  847 
Data are representative of at least two independent experiments. * P ≤ 0.05. 848 
 849 
Figure 5.  Oxidative stress-dependent IL-33 production is associated with enhanced ILC2 responses 850 
following neonatal hyperoxia. 851 
(A) Lung cytokine gene expression levels were measured by quantitative RT-PCR at PN7 or PN14. n=3 852 
to 5 mice per group (mean ± SEM). 853 
(B) Cytokine protein levels were determined by ELISA in the lung supernatants at PN21. n=3 mice per 854 
group (mean ± SEM). 855 
(C) MLE-12 cells were exposed to different concentrations of H2O2. Il33 gene expression was 856 
determined by quantitative RT-PCR. n=2 per group (mean ± SEM). 857 
(D) MLE-12 cells were exposed to H2O2 of 200 µM in the presence or absence of sulforalphane (SFN) 858 
and Il33 gene expression was determined by quantitative RT-PCR. n=2 per group (mean ± SEM). 859 
(E) MLE-12 cells were cultured under normoxia or hyperoxia condition for 24 hours in the presence or 860 
absence of SFN and then recovered in normoxia incubator for additional 24 hours. Il33 expression was 861 
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determined by quantitative RT-PCR. n=3 per group (mean ± SEM). 862 
(F) Neonatal mice were exposed to RA or O2 and treated with SFN. IL-33 protein levels were measured 863 
at PN21. n=2 or 3 mice per group (mean ± SEM). 864 
(G, H) Neonatal mice were exposed to RA or O2 and treated with SFN. Total ILC2 (G) or IL-13+ ILC2 865 
numbers were determined at PN28. n=4 or 8 mice per group (mean ± SEM). 866 
Data are representative of at least two independent experiments. n.s., not significant; * P ≤ 0.05.  867 
 868 
Fig. 6. Asthma-related gene expression and ILC2 responses are mediated by IL-33 signaling. 869 
(A) Lung asthma-related genes were measured by the mouse asthma and allergy RT2 PCR array at PN28.  870 
(B) Il5, Il13, Il21, arg1, Rnase2a and Pmch genes were confirmed by real-time PC . n=3 or 4 mice per 871 
group (mean ± SEM).  872 
(C) ILC2s in the lungs of WT or ST2-deficient mice were measured by flow cytometry at PN28. n=3 or 4 873 
mice per group (mean ± SEM). 874 
(D) Representative FACS plots and absolute numbers of IL-13 or IL-5 producing cells in the lungs of WT 875 
or ST2-deficient mice following RA or O2 exposure at PN28. n=2 or 4 mice per group (mean ± SEM). 876 
(E) The frequencies and absolute numbers of eosinophils in the airway of WT or ST2-deficient mice were 877 
determined by flow cytometry at PN28. n=3 or 4 mice per group (mean ± SEM). 878 
Data are representative of at least two independent experiments. n.s., not significant; * P ≤ 0.05. 879 
 880 
Fig. 7. Serum IL-33 levels correlate with IL-5 and IL-13 levels in preterm infants.  881 
IL-33, IL-5, IL-13 and IL-4 cytokine levels in the sera of preterm infants were measured by multiplex. 882 
Correlations between IL-33 and IL-5 (A), IL-13 (B) or IL-4(C) were evaluated by Pearson’s test using 883 
GraphPad Prism. 884 
 885 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Fig. 1. Gating strategy of ILC2s 
Lung single cells were isolated and stained with Lin (CD11b, CD11c, CD3, Gr-1, B220, TCRβ, 
Ter-119, NK1.1), ST2, CD90, CD25 and CD127. ILC2s were defined as Lin- CD25+ CD127+. 
 
Supplementary Fig. 2. Quantification of certain innate cell populations in the lungs of RA or O2-
exposed mice. 
Neonatal mice were exposed to RA or O2 for 7 days. Total DCs, FcεRI+ DCs, mast cells and 
basophils were quantified in the lungs at PN28. n=3 or 4 mice per group (mean ± SEM). * P ≤ 
0.05. 
 
Supplementary Fig. 3. Cytokine producing cells in the lungs of RA or O2 exposed-mice 
following HDM challenge. 
Cytokine producing cells in the lungs were measured by intracellular staining. n=4 mice per 
group (mean ± SEM). * P ≤ 0.05. 
 
Supplementary Fig. 4. Absolute numbers and frequencies of ILC2s in the lungs of RA or O2 
exposed-mice following chronic HDM challenge 
Mice were exposed to RA or O2 and challenged with HDM as in Fig. 4. Numbers or frequencies 
of ILC2s in the lungs were determined by flow cytometry at PN56. n=4 mice per group (mean ± 
SEM).  
 
Supplementary Fig.5. Neonatal hyperoxia promotes oxidative stress in the lungs. 
Neonatal mice were exposed to RA or O2 for 7 days and then housed in RA. (A) ROS levels in 
lung epithelial cells of RA or O2- exposed mice were determined by H2DCFDA staining at 
PN21. n=3 to 5 mice per group (mean ± SEM). * P ≤ 0.05. (B) Oxidative stress genes in the 
lungs of RA, O2- exposed or SFN-treated O2- exposed mice were measured through mouse 
oxidative stress RT2 PCR array at PN15.  
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Supplementary Fig. 6. IL-33 signaling enhances allergy and asthma gene expression. 
Gene expression fold changes were compared between indicated two groups. (A) WT RA group 
v.s. O2 group. (B) ST2-deficient RA v.s. O2 groups. (C) WT O2 group v.s. ST2 deficient O2 
group. 
 
Supplementary Fig. 7. Serum cytokine levels in Term or Preterm infants. 
Human sera from term or preterm infants were collected. IL-33, IL-5, IL-13 and IL-4 levels were 
determined by multiplex. (A) The levels of cytokines were represented by column graph. (B and 
C) Pie charts of the frequencies of indicated serum IL-33 concentration ranges in the groups of 
term infant, pre-term infant with or without BPD criteria (B), or in the groups of infants born 
before 30 weeks of gestational age, between 30 to 37 gestational age or over 37 gestational age 
(C).  
 
Supplementary Fig. 8. Correlation analysis of serum IL-33 and IL-13, and serum IL-33 and IL-5 
in term infants. 
Correlations between serum IL-33 and IL-5 or serum IL-33 and IL-13 were evaluated by 
Pearson’s test using GraphPad Prism. 
 
Supplementary Fig. 9. Correlation analysis of serum IL-33 and IL-13, and serum IL-33 and IL-5 
according to infant age groups. 
Correlations between serum IL-33 and IL-5 or serum IL-33 and IL-13 in samples collected from 
infants younger than 18 months or infants between 18 months and 30 months of age were 
evaluated by Pearson’s test using GraphPad Prism. 
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gender
gestational age 
(weeks)
age (mo) IL-33 (pg/ml) IL-13 (pg/ml) IL-5 (pg/ml) IL-4 (pg/ml)
1 M 40 7.6 1.85 n.d. 0.5 n.d.
2 F 38 14.5 26.18 29.12 4.15 n.d.
3 F 38 14.5 10.87 143.37 17.28 0.47
4 F 40 21.8 15.54 38.27 4.41 n.d.
5 M 39 14.2 4.22 11.68 1.24 n.d.
6 F 40 3.4 2.64 n.d. 0.84 3.35
7 F 39 18.9 26.76 174.24 26.73 24.38
8 M 38 6.3 n.d. n.d. 3.29 n.d.
9 M 38 6.5 5.8 n.d. 0.97 15.75
10 M 40 27.0 36.4 48.27 5.85 n.d.
11 F 40 25.2 n.d. 94.54 14.99 5.98
12 F 40 25.1 0.45 n.d. n.d. n.d.
13 F 40 8.8 n.d. n.d. 0.3 n.d.
14 F 39 11.4 2.84 n.d. 1.24 n.d.
15 F 40 29.0 5.8 n.d. 0.02 n.d.
16 M 40 10.1 0.65 n.d. 2.17 n.d.
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1 M 35 16.17 4.22 34.93 4.67 n.d.
2 F 32 7.87 n.d. n.d. 0.3 n.d.
3 F 32 7.87 n.d. n.d. n.d. n.d.
4 M 32 7.87 9.12 n.d. 2.04 9.74
5 F 30 9.50 8.34 n.d. 1.1 5.98
6 M 35 11.97 6.38 n.d. 0.43 n.d.
7 F 32 12.37 4.22 8.62 1.64 n.d.
8 F 32 12.37 3.83 33.8 3.09 n.d.
9 F 32 12.87 8.93 1.73 1.1 n.d.
10 M 32 12.87 3.44 5.62 1.24 n.d.
11 F 28 23.80 8.53 n.d. 1.5 n.d.
12 F 28 23.80 5.4 3.23 2.3 13.38
13 M 31 18.40 46.8 132.37 14.86 n.d.
14 M 34 12.70 n.d. n.d. 1.17 n.d.
15 F 30 15.20 13.01 89.07 9.38 12.18
16 M 31 21.33 n.d. 23.53 3.22 n.d.
17 M 32 11.80 3.83 n.d. 2.5 3.35
18 F 31 14.10 2.25 n.d. 0.84 n.d.
19 F 31 14.50 n.d. 14.46 2.83 n.d.
20 M 35 22.50 n.d. n.d. 1.1 n.d.
21 F 34 15.53 43.72 97.65 14.99 n.d.
22 M 34 22.23 29.85 108.66 9.65 10.36
23 F 30 19.23 n.d. n.d. n.d. n.d.
24 M 30 19.23 n.d. n.d. 0.7 n.d.
25 M 32 11.60 3.24 n.d. 0.84 n.d.
26 M 35 21.40 4.22 4.49 1.64 n.d.
27 F 35 21.40 11.26 n.d. 1.77 n.d.
28 M 29 14.53 4.42 n.d. 1.24 9.13
29 M 29 14.53 5.6 n.d. 0.84 n.d.
30 F 33 8.03 n.d. n.d. n.d. n.d.
31 M 33 8.03 n.d. n.d. n.d. n.d.
32 M 33 13.07 3.1 n.d. n.d. n.d.
33 M 31 12.10 9 9.72 1.78 14.47
34 M 30 23.33 131.56 122.59 14.33 0.12
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gendergestational age (weeks) age (mo) IL-33 (pg/ml) IL-13 (pg/ml) IL-5 (pg/ml) IL-4 (pg/ml)
1 F 24 20.07 1.45 n.d. 0.02 n.d.
2 F 24 20.10 1.45 n.d. 1.5 n.d.
3 M 26 27.53 n.d. n.d. 0.02 n.d.
4 F 28 15.07 3.04 n.d. 0.16 n.d.
5 M 29 25.53 93.18 1.73 1.24 n.d.
6 F 24 25.50 12.04 18.49 2.7 n.d.
7 F 25 23.43 4.81 n.d. 0.7 n.d.
8 F 24 19.47 18.25 n.d. n.d. n.d.
9 F 30 6.97 n.d. n.d. 0.7 n.d.
10 F 28 22.50 56.03 201.56 26.86 10.97
11 F 28 22.50 3.04 n.d. 0.57 n.d.
12 F 29 19.87 2.64 n.d. 1.1 n.d.
13 M 26 18.47 6.58 n.d. 1.37 n.d.
14 M 25 20.63 0.25 n.d. n.d. n.d.
15 M 26 24.10 1.65 n.d. 1.37 0.47
16 M 26 18.37 6.58 59.33 6.84 n.d.
17 F 33 13.03 2.25 n.d. 1.64 n.d.
18 M 26 23.60 22.9 50.29 7.03 19.24
19 F 24 25.07 59.69 7.67 2.5 10.97
20 F 26 25.53 75.66 207.14 29.87 16.92
21 F 25 17.37 n.d. n.d. 1.5 n.d.
22 M 28 10.33 n.d. n.d. 0.77 n.d.
23 F 28 8.23 1.85 n.d. 0.43 n.d.
24 F 27 24.40 13.99 n.d. 1.1 8.51
25 F 27 24.70 1.85 n.d. 1.24 n.d.
26 M 27 18.53 13.6 77.84 9.38 33.84
27 M 26 19.77 65.65 198.06 25.82 3.35
28 M 24 12.73 2.25 n.d. 2.96 14.56
29 M 27 13.03 5.8 n.d. 3.36 n.d.
30 M 26 10.27 3.04 n.d. 1.64 n.d.
31 M 29 18.57 8.93 n.d. 0.7 1.24
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no BPDgender gestational age 
(weeks)
age (mo) IL-33 (pg/ml) IL-13 (pg/ml) IL-5 (pg/ml) IL-4 (pg/ml)
1 M 35 16.17 4.22 34.93 4.67 n.d.
2 F 32 7.87 n.d. n.d. 0.3 n.d.
3 F 32 7.87 n.d. n.d. n.d. n.d.
4 M 32 7.87 9.12 n.d. 2.04 9.74
5 F 30 9.50 8.34 n.d. 1.1 5.98
6 M 35 11.97 6.38 n.d. 0.43 n.d.
7 F 32 12.37 4.22 8.62 1.64 n.d.
8 F 32 12.37 3.83 33.8 3.09 n.d.
9 F 32 12.87 8.93 1.73 1.1 n.d.
10 M 32 12.87 3.44 5.62 1.24 n.d.
11 F 28 23.80 8.53 n.d. 1.5 n.d.
12 F 28 23.80 5.4 3.23 2.3 13.38
13 M 31 18.40 46.8 132.37 14.86 n.d.
14 M 34 12.70 n.d. n.d. 1.17 n.d.
15 F 30 15.20 13.01 89.07 9.38 12.18
16 M 31 21.33 n.d. 23.53 3.22 n.d.
17 M 32 11.80 3.83 n.d. 2.5 3.35
18 F 31 14.10 2.25 n.d. 0.84 n.d.
19 F 31 14.50 n.d. 14.46 2.83 n.d.
20 M 35 22.50 n.d. n.d. 1.1 n.d.
21 F 34 15.53 43.72 97.65 14.99 n.d.
22 M 34 22.23 29.85 108.66 9.65 10.36
23 F 30 19.23 n.d. n.d. n.d. n.d.
24 M 30 19.23 n.d. n.d. 0.7 n.d.
25 M 32 11.60 3.24 n.d. 0.84 n.d.
26 M 35 21.40 4.22 4.49 1.64 n.d.
27 F 35 21.40 11.26 n.d. 1.77 n.d.
28 M 29 14.53 4.42 n.d. 1.24 9.13
29 M 29 14.53 5.6 n.d. 0.84 n.d.
30 F 33 8.03 n.d. n.d. n.d. n.d.
31 M 33 8.03 n.d. n.d. n.d. n.d.
32 M 33 13.07 3.1 n.d. n.d. n.d.
33 M 31 12.10 9 9.72 1.78 14.47
34 M 30 23.33 131.56 122.59 14.33 0.12
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BPD gender gestational age 
(weeks)
age (mo) IL-33 (pg/ml) IL-13 (pg/ml) IL-5 (pg/ml) IL-4 (pg/ml)
1 F 24 20.07 1.45 n.d. 0.02 n.d.
2 F 24 20.10 1.45 n.d. 1.5 n.d.
3 M 26 27.53 n.d. n.d. 0.02 n.d.
4 F 28 15.07 3.04 n.d. 0.16 n.d.
5 M 29 25.53 93.18 1.73 1.24 n.d.
6 F 24 25.50 12.04 18.49 2.7 n.d.
7 F 25 23.43 4.81 n.d. 0.7 n.d.
8 F 24 19.47 18.25 n.d. n.d. n.d.
9 F 30 6.97 n.d. n.d. 0.7 n.d.
10 F 28 22.50 56.03 201.56 26.86 10.97
11 F 28 22.50 3.04 n.d. 0.57 n.d.
12 F 29 19.87 2.64 n.d. 1.1 n.d.
13 M 26 18.47 6.58 n.d. 1.37 n.d.
14 M 25 20.63 0.25 n.d. n.d. n.d.
15 M 26 24.10 1.65 n.d. 1.37 0.47
16 M 26 18.37 6.58 59.33 6.84 n.d.
17 F 33 13.03 2.25 n.d. 1.64 n.d.
18 M 26 23.60 22.9 50.29 7.03 19.24
19 F 24 25.07 59.69 7.67 2.5 10.97
20 F 26 25.53 75.66 207.14 29.87 16.92
21 F 25 17.37 n.d. n.d. 1.5 n.d.
22 M 28 10.33 n.d. n.d. 0.77 n.d.
23 F 28 8.23 1.85 n.d. 0.43 n.d.
24 F 27 24.40 13.99 n.d. 1.1 8.51
25 F 27 24.70 1.85 n.d. 1.24 n.d.
26 M 27 18.53 13.6 77.84 9.38 33.84
27 M 26 19.77 65.65 198.06 25.82 3.35
28 M 24 12.73 2.25 n.d. 2.96 14.56
29 M 27 13.03 5.8 n.d. 3.36 n.d.
30 M 26 10.27 3.04 n.d. 1.64 n.d.
31 M 29 18.57 8.93 n.d. 0.7 1.24
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